About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Multimodal Managements for Metastatic Pancreatic Cancer.

NCT06967233·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Zhejiang University

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adult patients aged ≥18 years (at diagnosis).
Cytologically or histologically confirmed pancreatic adenocarcinoma.
Synchronous liver metastatic disease (at diagnosis).
No evidence of extrahepatic metastases (at diagnosis.)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
Eligible for multimodal treatment.

You may not be if

Multi-organ metastatic pancreatic cancer.
Contraindications to surgical resection or systemic treatment.
Inability to participate in follow-up assessments.
History of other malignancies.
Refusal of treatment.

The record

StatusCompleted

PhaseNo phase

Taking part360

StartedJun 2019

UpdatedMay 13, 2025

Conditions

Metastatic Pancreatic Cancer

Where1

The first affiliated hospital, Zhejiang university school of medicine
Hangzhou, Zhejiang, China

Clareo Health | Multimodal Managements for Metastatic Pancreatic Cancer.